Showing results (481-490 of 512) with videos related to

Sort By:
Pageof 52
Gut|February 26, 2015
Developing in vitro expanded CD45RA+ regulatory T cells as an adoptive cell therapy for Crohn's diseaseJames B Canavan, Cristiano Scottà, Anna Vossenkämper, et al.
ACS Applied Materials & Interfaces|February 2, 2026
Milling-Induced Defect Engineering of Zr-Based Metal-Organic Frameworks and Its Catalytic ApplicationsGeorgina P Robertson, Emily V Shaw, Florencia A Son, et al.
The Lancet. Gastroenterology & Hepatology|January 13, 2022
Therapeutic drug monitoring of biologics in inflammatory bowel disease: unmet needs and future perspectivesKonstantinos Papamichael, Waqqas Afif, David Drobne, et al.
Journal of Crohn'S & Colitis|May 24, 2022
Thromboprophylaxis Use in Paediatric Inflammatory Bowel Disease: An International RAND Appropriateness PanelFranco Torrente, Susanna Meade, Eric I Benchimol, et al.
Thorax|May 28, 2021
RAND appropriateness panel to determine the applicability of UK guidelines on the management of acute respiratory distress syndrome (ARDS) and other strategies in the context of the COVID-19 pandemicMark Griffiths, Susanna Meade, Charlotte Summers, et al.
Circulation. Heart Failure|November 22, 2021
Contemporary Management of Cardiogenic Shock: A RAND Appropriateness Panel ApproachAlastair G Proudfoot, Antonis Kalakoutas, Susanna Meade, et al.
Frontline Gastroenterology|August 26, 2017
Vedolizumab: early experience and medium-term outcomes from two UK tertiary IBD centresMark A Samaan, Polychronis Pavlidis, Emma Johnston, et al.
Frontline Gastroenterology|September 3, 2020
Organisational changes and challenges for inflammatory bowel disease services in the UK during the COVID-19 pandemicNicholas A Kennedy, Richard Hansen, Lisa Younge, et al.
Gastroenterology|October 11, 2019
HLA-DQA1*05 Carriage Associated With Development of Anti-Drug Antibodies to Infliximab and Adalimumab in Patients With Crohn's DiseaseAleksejs Sazonovs, Nicholas A Kennedy, Loukas Moutsianas, et al.
The New England Journal of Medicine|July 17, 2024
Risankizumab versus Ustekinumab for Moderate-to-Severe Crohn's DiseaseLaurent Peyrin-Biroulet, J Casey Chapman, Jean-Frederic Colombel, et al.
Pageof 52